Clinico-toxicological effects of ceftriaxone after intramuscular administration of graded doses in Basenji dogs
| Autor: | Isaac Uzoma Asuzu, Boniface M. Anene, Ifeanyi G. Eke, Aruh O. Anaga, Ekene V. Ezenduka, Elias Abah, Ikechukwu J. Udeani, Ukamaka U. Eze, Chuka Ezema |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Tachycardia
medicine.medical_specialty Hematology biology business.industry Pharmaceutical Science Gastroenterology Alanine transaminase Ceftriaxone Dogs Haematology Physiological parameters Toxicity Internal medicine Toxicity Heart rate Ceftriaxone medicine biology.protein Alkaline phosphatase Pharmacology (medical) medicine.symptom Adverse effect business medicine.drug |
| Zdroj: | Tropical Journal of Pharmaceutical Research; Vol. 20 No. 10 (2021); 2089-2097 |
| ISSN: | 1596-5996 1596-9827 |
| Popis: | Purpose: The recent ceftriaxone-induced anaemia and mortalities at the dose of 50 mg/kg in Veterinary Teaching Hospital, University of Nigeria prompted this study which sought to assess the clinicotoxicological effects of ceftriaxone (CFZ) after intramuscular administration of graded doses in Basenji dogs.Methods: The effects of CFZ on the haematological indices, physiological parameters, liver and kidney functions were assessed in 4 group of dogs (n = 4) designated A – D. They were given CFZ intramuscularly for 21 days at doses of 12, 25 and 50 mg/kg for groups A, B, C, respectively, while thecontrol (group D) received the diluent (lignocaine 0.2 mL)Results: The mean pulse and heart rate of dogs in group C were significantly (p < 0.05) higher than those of group A, B and D. Significant (p < 0.05) decrease in red blood cell count (RBC), haemoglobin concentration (Hb) and packed cell volume (PCV) was observed in group C on days 7 and 14, while on day 21, these parameters were significantly (p < 0.05) higher in group D than in the treated groups. On day 14 of CFZ administration, the alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) activities of dogs in group C was significantly (p < 0.05) elevated than the control group.Conclusion: These findings suggest that CFZ, at the doses of 12.5 - 25 mg/kg, appears safe in dogs as most of the adverse effects observed are reversed following the withdrawal of the drug on day 28. However, CFZ at 50 mg/kg causes anaemia, tachycardia and bilateral paralysis of the hind limbs which did not revert to normal after one week; hence, it is not recommended for use in dogs at this dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|